These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 19414887

  • 1. Improving mental health treatments through comparative effectiveness research.
    Wang PS, Ulbricht CM, Schoenbaum M.
    Health Aff (Millwood); 2009; 28(3):783-91. PubMed ID: 19414887
    [Abstract] [Full Text] [Related]

  • 2. Trends in mental health cost growth: an expanded role for management?
    Frank RG, Goldman HH, McGuire TG.
    Health Aff (Millwood); 2009; 28(3):649-59. PubMed ID: 19414870
    [Abstract] [Full Text] [Related]

  • 3. Implementing effectiveness research and improving care for schizophrenia in real-world settings.
    Buckley PF, Miller A, Chiles JA, Sajatovic M.
    Am J Manag Care; 1999 Jun 25; 5 Spec No():SP47-56. PubMed ID: 10538860
    [Abstract] [Full Text] [Related]

  • 4. What explains the diffusion of treatments for mental illness?
    Drake R, Skinner J, Goldman HH.
    Am J Psychiatry; 2008 Nov 25; 165(11):1385-92. PubMed ID: 18981070
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of drug treatment history on comparative effectiveness research in schizophrenia.
    McCombs J, Zolfaghari S, Ganapathy V.
    Value Health; 2011 Nov 25; 14(5):679-86. PubMed ID: 21839406
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost of treating mental illness from a managed care perspective.
    Docherty JP.
    J Clin Psychiatry; 1999 Nov 25; 60 Suppl 3():49-52; discussion 53. PubMed ID: 10073378
    [Abstract] [Full Text] [Related]

  • 12. [Off-label applications (professional rationales, financial possibilities)].
    László P.
    Neuropsychopharmacol Hung; 2007 Oct 25; 9(3):111-2. PubMed ID: 18399028
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacoeconomics of schizophrenia in the 21st century.
    Hanson MA.
    J Clin Psychiatry; 1999 Oct 25; 60 Suppl 1():26-7; discussion 28-30. PubMed ID: 10037168
    [Abstract] [Full Text] [Related]

  • 14. Stepped care: doing more with less?
    Davison GC.
    J Consult Clin Psychol; 2000 Aug 25; 68(4):580-5. PubMed ID: 10965633
    [Abstract] [Full Text] [Related]

  • 15. Methodological challenges in psychiatric treatment adherence research.
    Velligan D, Sajatovic M, Valenstein M, Riley WT, Safren S, Lewis-Fernandez R, Weiden P, Ogedegbe G, Jamison J.
    Clin Schizophr Relat Psychoses; 2010 Apr 25; 4(1):74-91. PubMed ID: 20643631
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Evidence data and importance of public health of the new antipsychotics].
    Launois R.
    Encephale; 2006 Oct 25; 32(5 Pt 3):S861-5. PubMed ID: 17119488
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An outcomes-based approach to decisions about drug coverage policies in British Columbia.
    Morgan S, Bassett K, Mintzes B.
    Psychiatr Serv; 2004 Nov 25; 55(11):1230-2. PubMed ID: 15534010
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.